Esco Ventures Advisory Board
Esco Ventures, the corporate venture arm of Esco Group, and also a leading Asia based global biotech venture builder via its Esco Ventures X arm, is proud to announce the expansion of its global advisory board.
Prof Harvey Lodish of MIT's Whitehead Institute and Dr. Bertil Lindmark, former VP of AstraZeneca, have recently joined Esco Ventures' advisory board. Prof Lodish has been a co founder of multiple biotech companies, including Genzyme, Millennium Pharmaceuticals and more recently Rubius Therapeutics, which went public in 2018 and achieved a market cap of 1.8B. Dr. Lindmark was formerly a VP at AstraZeneca, where he led the clinical development of respiratory products, headed the clinical division of AstraZeneca Japan, and more recently served as CSO of Almirall, CMO of Aslan Pharmaceuticals and is currently CMO at eTheRNA Immunotherapies.
These appointments enhance Esco Ventures' reach into the Boston and European ecosystems. In totality, the Esco Ventures advisory board now has a balanced set of networks and skill sets including academic science, big pharma clinical development, classical therapeutic modalities (ie small molecules and antibodies), novel therapeutic modalities (cell and gene therapy), rare diseases, mRNA therapeutics, oncology, women's health, and access to VC and pharma networks across the US, Europe and China.
Prof. Harvey Lodish, is a Founding Member of The Whitehead Institute as well as the Founder & Scientific Advisory board member of Genzyme, Arris Pharmaceuticals, Millennium Pharmaceuticals, Allozyne, Rubius Therapeutics and several other biotech companies.
Dr. Bertil Lindmark is Chief Medical Officer (CMO) of eTheRNA Immunotherapies. Prior to eTheRNA, he was also the CMO at ASLAN and before that, the Executive Director of Research and Development and a Member of the Board of Directors at Almirall SA, a public European pharmaceutical company. Even prior, he was Vice President at AstraZeneca, leading global clinical development in Respiratory and Inflammation. He also served as Vice President and Head of Clinical Development at AstraZeneca, Japan R&D.